Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382954 · ClinicalTrials.gov registry record · Phase 1
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
A Phase 1 study, sponsored by University of Kentucky.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT00382954: Completed Phase 1 study, sponsored by University of Kentucky.
NCT00382954 is a Phase 1 study that has completed, run by University of Kentucky. The registered enrollment target is 55 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00382954, a Phase 1 study, has completed, sponsored by University of Kentucky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximal tolerated dose (MTD) of bortezomib and idarubicin given in combination to newly diagnosed AML patients \>60 years or relapsed AML patients. Another purpose of this study is to determine the dose limiting toxicities associated with bortezomib in combination with idarubicin in newly diagnosed AML patients \>60 years or relapsed AML patients.
Interventions
- DRUG Idarubicin
- DRUG Velcade
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2004-02 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
What the finished NCT00382954 record still lists
NCT00382954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Idarubicin is the first listed.
NCT00382954 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00382954 about?
NCT00382954 is a clinical study titled "Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML". The purpose of this study is to determine the maximal tolerated dose (MTD) of bortezomib and idarubicin given in combination to newly diagnosed AML patients \>60 years or relapsed AML patients. Another purpose of this study is to determine the dose limiting toxicities associated with bortezomib in ...
What is the current status of trial NCT00382954?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2004-02. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00382954?
The interventions under investigation include: Idarubicin (DRUG), Velcade (DRUG).
Who is sponsoring clinical trial NCT00382954?
This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00382954's enrollment target sits among peer trials
55 918th of 2000 higher than 1,070 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia